Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma

N Syed1, J Langer1, K Janczar1, P Singh1, C Lo Negro2, L Lattanzio2, HM Coley3, E Hatzimichael4, J Bomalaski5, P Szlosarek6, M Awad7, K O’Neil7, F Roncaroli1 and T Crook8

Arginine deprivation, either by nutritional starvation or exposure to ADI-PEG20, induces adaptive transcriptional upregulation of ASS1 and ASL in glioblastoma multiforme ex vivo cultures and cell lines. This adaptive transcriptional upregulation is blocked by neoplasia-specific CpG island methylation in either gene, causing arginine auxotrophy and cell death. In cells with methylated ASS1 or ASL CpG islands, ADI-PEG20 initially induces a protective autophagic response, but abrogation of this by chloroquine accelerates and potentiates cytotoxicity. Concomitant methylation in the CpG islands of both ASS1 and ASL, observed in a subset of cases, confers hypersensitivity to ADI-PEG20. Cancer stem cells positive for CD133 and methylation in the ASL CpG island retain sensitivity to ADI-PEG20. Our results show for the first time that epigenetic changes occur in both of the two key genes of arginine biosynthesis in human cancer and confer sensitivity to therapeutic arginine deprivation. We demonstrate that methylation status of the CpG islands, rather than expression levels per se of the genes, predicts sensitivity to arginine deprivation. Our results suggest a novel therapeutic strategy for this invariably fatal central nervous system neoplasm for which we have identified robust biomarkers and which overcomes the limitations to conventional chemotherapy imposed by the blood/brain barrier.

Cell Death and Disease (2013) 4, e458; doi:10.1038/cddis.2012.197; published online 17 January 2013

Subject Category: Cancer

Glioblastoma multiforme (GBM) is the most common primary human malignant brain tumour and is among the most lethal of all cancers. Despite advances in surgical management and radiotherapy, and development of temozolomide, the median survival for patients is 12–16 months. The unfavourable prognosis in this disease is strongly correlated to the intrinsic radio-resistant CD133 cancer stem cells (CSCs). A further barrier to effective therapy of GBM is the presence of the blood/brain barrier, which limits access of chemotherapy to the central nervous system. These considerations clearly underline the urgent need for novel therapeutic approaches. GBM cells are less sensitive to apoptosis, yet less resistant to therapies that induce autophagy, Temozolomide, the most active agent in treating GBM, exerts cytotoxicity by inducing autophagic cell death. Autophagy is a non-apoptotic route of programmed cell death involving the formation of large double-membrane autophagic vacuoles termed autolysosomes to degrade and recycle long-lived organelles and proteins by merging with lysosomes to form autolysosomes. Autophagy has a critical role in cellular survival during periods of starvation, but when stress conditions are excessive, autophagy becomes a cellular suicide pathway. As such, autophagy is initially an adaptive response to ensure survival but beyond a certain threshold may mediate a form of non-caspase-mediated cell death.

Tumour cells have a high requirement for arginine. This semi-essential amino acid is synthesized from citrulline via the urea cycle enzymes argininosuccinate synthetase (ASS) and argininosuccinate lyase (ASL). In a subset of human cancers, ASS expression is lost rendering them highly sensitive to deprivation of arginine by pegylated arginine deiminase (ADI-PEG20). ADI-PEG20 induces autophagic cell death in melanoma and in prostate carcinoma. ASS and ASL are tightly coupled and upregulated
Previous studies have identified a number of genes subject to methylation-dependent transcriptional silencing in high-grade brain tumours. To seek additional epigenetically regulated genes in GBM, we performed methylation reversal and micro-array analysis in GBM cell lines. Here, we describe the identification and characterization of the two key enzymes in arginine biosynthesis, ASS1 and ASL, as epigenetically regulated genes in GBM, and we demonstrate that epigenetic changes in these changes modulate cellular sensitivity to therapeutic autophagy.

**Results**

**Methylation reversal identifies novel methylated genes in GBM.** We used 5-Aza-2'-deoxycytidine (5'AZA) to reverse transcriptional silencing in the GAMG GBM cell line. mRNAs upregulated by demethylation were identified by micro-array analysis. The mRNA of 47 genes was upregulated at least twofold by 5'AZA and of 791 genes at least 1.4-fold. We selected 10 genes and confirmed upregulation by 5'AZA for 7 of them (Figure 1a). Among the genes upregulated by 5'AZA in GAMG cells was ASS1, which contains a CpG island in the 5' regulatory sequences of the gene (see Supplementary Figure S1 for map of CpG island, including location of primers). This gene encodes ASS, the enzyme catalysing the rate-limiting step in arginine biosynthesis. Using quantitative PCR (qPCR) and western blotting, we confirmed upregulation of ASS1 mRNA by 5'AZA in the GAMG GBM cell line but not in the 42MG cell line (Figure 1b). Using methylation-specific PCR (MSP), we confirmed that the increased expression of ASS1 in following 5'AZA is accompanied by a decrease in CpG island methylation that does not occur in 42MG (Figure 1b).

**Silencing of ASS1 in primary cultures of GBM.** To investigate in detail the potential epigenetic regulation of ASS1, we established 22 primary GBM cultures from tissue obtained at first surgical debulking of patients in our clinical practice. These early passage cultures were tested for expression and methylation of ASS1. Downregulation of ASS1 mRNA and protein was observed in 8/22 cases, results are shown for 10 cases (Figure 1c). Using MSP and pyrosequencing, all cases with ASS1 methylation had downregulation of ASS1 mRNA (GBM 31, 53 and 59). However, in some cases, ASS1 mRNA was downregulated

---

**Figure 1** Methylation-dependent transcriptional silencing of ASS1 in GBM. (a) Expression of novel candidate genes is upregulated by demethylation. The figure shows qPCR analysis of the indicated genes in GAMG cells treated (black) or untreated (clear) with 5'AZA. Experiments were performed in triplicate and data shown are mean fold increases (+/− 1 S.D.) in 5'AZA-treated cells relative to control cells treated with dimethylsulphoxide. (b) 5'AZA upregulates ASS1 in GAMG but not 42MG cells. The top panel shows qPCR, the middle panel MSP and the bottom panel western blot analysis of ASS in GAMG and 42MG cells with and without exposure to 5'AZA as indicated. Actin is used as a loading control for the western blot. (c) qPCR and western blot analysis of ASS1 in primary GBM explants. qPCR was performed in triplicate and data shown are expression relative to GBM 7 (+/− 1 S.D.). (d) MSP analysis of ASS1 CpG island in primary GBM explants. The figure shows unmethylated (U) and methylated (M) reactions for each case. Also shown are control U and M DNA samples modified in parallel with the experimental DNA samples. (e) Pyrosequencing analysis of ASS1 CpG island in primary GBM explants. The level of methylation in individual CpG dinucleotides is indicated by the intensity of shading as shown.
but without detectable methylation in the CpG island (GBM 6, 27, 25 and 41; Figures 1d and e).

**ASL is silenced in primary GBM.** ASS catalyses the rate-limiting step in arginine biosynthesis prompting us to ask whether expression of ASL, the next enzyme in the arginine biosynthetic pathway, is also downregulated in GBM. As no antibodies recognizing ASL protein exist, we analysed expression of ASL using qPCR. Downregulation of ASL mRNA was observed in 5/22 primary GBM cultures, results are shown for 10 primary cultures (Figure 2a). As with ASS1, there is a CpG island in the regulatory sequences of ASL (Supplementary Figure S1). Using MSP and pyrosequencing, we showed that each of the primary GBM with downregulation of ASL was methylated in the ASL CpG island (Figures 2b and c). To confirm the role of CpG island methylation, we treated cells with AZA and observed upregulation of ASL in GBM 59 (CpG island methylated) but no effect on ASL levels in GBM 6 (CpG island unmethylated). Following AZA, there was a reduction in CpG island methylation in GBM 59 (Figure 2d).

As was observed for ASS1, there were cases in which ASL mRNA was downregulated but without detectable methylation in the CpG island (GBM 16 and 41).

**Methylation abrogates adaptive transcriptional upregulation of ASS1 and ASL and confers arginine auxotrophy.** As ASS1 and ASL are key enzymes in the biosynthesis of arginine, we tested the effects of arginine deprivation on the growth of primary GBM cultures using the enzyme ADI-PEG20. We first performed a detailed dose response analysis and showed that the presence of CpG island methylation in either ASS1 or ASL CpG island was associated with sensitivity to the anti-proliferative effects of ADI-PEG20 (GBM 31, 27), whereas cells in which the CpG islands of ASS1 and ASL were unmethylated were insensitive to ADI-PEG20 (GBM 16) (Figure 3c and Supplementary Table S2). Cells with methylation in both CpG islands were hypersensitive to the drug, with complete inhibition of growth at a concentration of 0.06 μg/ml (GBM 59) (Figure 3c). For analysis of ASS1 and ASL gene expression, qPCR and western blotting were performed 48 h post treatment. ADI-PEG20 induced robust upregulation of ASS1 and ASL mRNA and ASS protein in unmethylated lines as shown in Figures 3a and b, respectively. This adaptive upregulation was absent in cells with CpG island methylation, but upregulation was readily induced in these cells by 5’AZA. These results suggest that CpG island methylation in ASS and ASL, rather than absolute expression levels per se, is the critical determinant of sensitivity to ADI-PEG20.

To confirm these results, a panel of GBM cell lines were similarly tested. We confirmed that both ASS1 and ASL are subject to methylation-dependent transcriptional silencing (Supplementary Figure S2) and that CpG island methylation is a critical determinant of sensitivity to ADI-PEG20 (Supplementary Figure S3 and Supplementary Table S2).

**Knock down confirms the role of ASS1 in ADI-PEG20 sensitivity.** To further verify the role of ASS1 in sensitivity to ADI-PEG20, we generated stable knockdown cells of ASS1

**Figure 2**  Methylation-dependent transcriptional silencing of ASL (a) qPCR analysis of ASL in primary GBM explants. qPCR was performed in triplicate and data shown are expression relative to GBM 6 (+/-1 SD). (b) MSP analysis of ASL CpG island in primary GBM explants. The figure shows unmethylated (U) and methylated (M) reactions for each case. Also shown are control U and M DNA samples modified in parallel with the experimental DNA samples. (c) Pyrosequencing analysis of ASL CpG island in primary GBM explants. The level of methylation in individual CpG dinucleotides is indicated by the intensity of shading as shown. (d) 5’AZA upregulates ASL in primary GBM 59 but not in primary GBM 6 cells. The top panel shows qPCR and the bottom panel MSP analysis of ASL in GBM 59 and GBM 6 cells with and without exposure to 5’AZA as indicated.
sensitivity to ADI-PEG20

By contrast, GBM16 (described in Methods. The most sensitive tumour is GBM 59 in which both ASS1 methylation status. Logarithmic phase primary GBM cells were exposed to the indicated concentrations of ADI-PEG20 and proliferation assessed by measurement of SRB as

Emami 2011) and others have shown that ASS1 is silenced in a variety of cancer cell types, through methylation. ASS1 expression is also subject to epigenetic effects. Previous studies have shown that ASS1 silencing sensitizes cells to autophagy and augments the cytotoxicity of ADI-PEG20. In the present study, we assess the role of ASS1 expression in response to ADI-PEG20 in primary GBM explants. ASS1 silencing sensitizes cells to autophagy and augments the cytotoxicity of ADI-PEG20.

The presence of CSCs in GBM is thought to confer resistance to conventional therapeutic strategies. Arginine auxotrophic CSCs are sensitive to ADI-PEG20.

Arginine auxotrophic GBM CSCs are sensitive to ADI-PEG20. The presence of CSCs in GBM is thought to be associated with resistance to temozolomide and treatment failure. Targeting these cells is therefore critical. Using flow cytometry, we detected a population of stem cells in the DBTRG GBM cell line (ASL methylated, partial sensitivity to ADI-PEG20) using the putative stem cell marker, CD133 (Figure 4b, upper panel). To test the effect of ADI-PEG20 on the CD133+ component, sorted cells were challenged with ADI-PEG20 and analysed for proliferation. Both populations of cells were equally inhibited in the presence of ADI-PEG20 (Figure 4b, lower panel).

Methylation of ASS1 sensitzes cells to autophagy upon arginine deprivation. Previous studies have shown that ADI-PEG20 induces autophagy in some ASS-negative cell lines, but the relationship to epigenetic status is unknown. As autophagy is a protective response to conditions of nutrient deprivation, we were interested to determine whether ADI-PEG20 was initially inducing an autophagic response in GBM cells. To investigate this, cell lines were exposed to ADI-PEG20 and analysed for markers of autophagy by western blotting (upregulation of Beclin 1 and the Atg genes 5 and 7, degradation of P62 and the conversion of cytosolic LC3-1 to the lipidated form LC3-II) and acridine orange staining (formation of acidic vesicular organelles). Acidic vesicular organelles are a characteristic feature of autophagy and can be detected and measured by vital staining with acridine orange, which accumulates in these acidic compartments, and is detectable as bright red fluorescence. Typical autophagic changes were detectable as early as 6 h after ADI-PEG20 treatment and progressively accumulated at 16 and 24 h in the ASS1-methylated line LN229 only (Figure 4c). Similarly, acidic vesicular organelles were only detected in this line and not in the unmethylated line T98G (Figure 4d). Treatment with bafilomycin A1, a specific inhibitor of vacuolar-type H+ ATPase, abrogated the formation of acidic vesicular organelles and no fluorescence was observed (Figure 4d).

using the T98G cell line. Having confirmed knock down by qPCR and western blotting (Figure 4a, upper panel), we showed that reduced levels of ASS1 confer sensitivity to ADI-PEG20 (Figure 4a, lower panel).

Figure 3 Methylation in the ASS1 and ASL CpG islands blocks transcriptional upregulation upon arginine deprivation and confers arginine auxotrophy and sensitivity to arginine deiminase (ADI-PEG20) in primary GBM explants. (a) Arginine deprivation induces ASS1 and ASL mRNA in primary GBM cells, but this is abrogated by CpG island methylation. The indicated GBM explants were grown in the presence of ADI-PEG20 (1 μg/ml) or 5’AZA (1 μM) as shown. RNA was harvested after 48 h and subjected to qPCR analysis of ASS1 and ASL as indicated. Each experiment was performed at least twice and the values shown are means (± SEM) relative to untreated control cells. (b) Western blot analysis of ASS in primary GBM cells. The indicated primary explants were grown in the presence of ADI-PEG20 (1 μg/ml) or 5’AZA (1 μM) as shown. ASS levels were analysed by western blotting after 48 h. Actin is used as a control protein. (c) Dose response curves for ADI-PEG20 in primary GBM of varying CpG island methylation status. Logarithmic phase primary GBM cells were exposed to the indicated concentrations of ADI-PEG20 and proliferation assessed by measurement of SRB as described in Methods. The most sensitive tumour is GBM 59 in which both ASS1 and ASL CpG islands are methylated and which is fully inhibited by 0.06 μg/ml ADI-PEG20. By contrast, GBM16 (ASS1 and ASL unmethylated) is unaffected by ADI-PEG20. GBM 27 and GBM 31 (either ASS1 or ASL CpG islands methylated) show intermediate sensitivity to ADI-PEG20

Expression of ASS1 and ASL in primary GBM cells was assessed by qPCR and western blotting. ASS1 expression was significantly upregulated in the presence of ADI-PEG20 in both ASS1 methylated lines GBM 59 and GBM 31 (either ASS1 or ASL CpG islands methylated) but not in the unmethylated line T98G. This upregulation was abrogated by 0.06 μg/ml ADI-PEG20 and was fully restored when the unmethylated line T98G was treated with 5’AZA (1 μM). Western blotting confirmed the qPCR results and showed that ASS1 and ASL expression was upregulated in the presence of ADI-PEG20 in both ASS1 methylated lines GBM 59 and GBM 31 (either ASS1 or ASL CpG islands methylated) but not in the unmethylated line T98G. This upregulation was abrogated by 0.06 μg/ml ADI-PEG20 and was fully restored when the unmethylated line T98G was treated with 5’AZA (1 μM).
Chloroquine (CQ) inhibits autophagy and accelerates ADI-PEG20 induced cell death. To test the hypothesis that ADI-PEG20 induced autophagy is (at least initially) a survival strategy for GBM cells, we investigated the effect of CQ, an inhibitor of autophagy. CQ efficiently blocked ADI-PEG20-induced p62 degradation and increased LC3-1 to LC3-11 conversion in the ASS1-methylated cell line LN229 (Figure 5a). These results are consistent with the fact that CQ acts late in autophagy, resulting in the accumulation of lipidated LC3-11. To further verify autophagy, stable LN229 cell lines expressing GFP-LC3 were generated to visualize autophagosome formation in real time in live cells. During autophagosome formation, GFP-LC3B is processed and recruited to the autophagosome membrane where it can be imaged as cytoplasmic puncta by high resolution fluorescence microscopy. Punctate GFP staining could be detected in ADI-PEG20-treated cells, which accumulated in the presence of CQ. This is consistent with the fact that CQ inhibits autophagic flux of LC3 (Figure 5b). No punctate staining was observed in GFP vector control cells.

To examine the effect of CQ on ADI-PEG20-induced cell death, cells were treated with either or both CQ and ADI-PEG20 and analysed by flow cytometry for sub-G1 content using propidium iodide. CQ accelerated and enhanced ADI-PEG20-induced cell death in cells with methylation in either the ASS1 or ASL CpG island as evidenced by an increase in the sub-G1 compartment (Figure 5c). By contrast, there was no effect of CQ in cells lacking methylation in the ASS1 and ASL CpG islands (Figure 5c). In methylated lines, cell death was first detectable at 72 h following treatment with ADI-PEG20 alone. However, in combination with CQ, cell death could be detected at 48 h. By 72 h, CQ further increased ADI-PEG20-induced cell death (Figure 5c).

Caspase inhibitors do not prevent ADI-PEG20-induced cell death. To determine the role of caspases in ADI-PEG20-induced cell death, a caspase inhibition assay was performed. LN229 (ASS1 methylated) and T98G (ASS1 and ASL unmethylated) cells were pre-treated with the pan caspase inhibitor Z-VAD and then exposed to ADI-PEG20. Cells were then harvested for assessment of cell death using propidium iodide and FITC-annexin. Treatment of cells with Z-VAD
alone had no effect on cell death in either LN229 or T98G (Figure 5d). Caspase-independent cell death was observed in LN229 (51%) but not T98G cells when pre-treated with Z-VAD in the presence of ADI-PEG20. There was a higher percentage of cell death in LN229 treated with ADI-PEG20 alone (78%), suggesting that 27% of cell death is attributable to caspases.

**ASS1 and ASL are frequent targets for epigenetic inactivation in clinical cases of GBM.** In order to translate these results into the clinical setting, we examined the two genes in clinical cases of human GBM using immunohistochemistry, MSP and pyrosequencing. Previous studies on ASS in melanoma, ovarian carcinoma and osteocarcinoma showed focal expression in tumour tissue. There are no published data on the expression of ASL in tumour tissue. Sixty patients (36 male, 24 female, median age 57 years) were retrospectively studied for ASS and ASL methylation and, of these cases, 55 were evaluated for ASS expression and 57 for ASL expression using a semi-quantitative scoring system as described in Methods. Representative ASS and ASL immunostaining and MSP in clinical cases are shown in Figures 6b and d. The methylation status of primary cells generated from some of these primary tumours is also shown (Figure 6d). These primary lines were stained for GFAP, a putative astrocyte marker and H&E stained (Figure 6a). All cases were further characterized by staining for p53, IDH1 and EGFR, CD133 and MGMT methylation (data not shown).

In all, 13/55 samples were negative for ASS expression by immunohistochemistry and scored 0. These negative cases correlated well with MSP and pyrosequencing data. A further 15 cases were methylated by MSP and had pyrosequencing values > 5, an arbitrary cutoff for methylation positivity. Eleven of these cases had low ASS staining (score 1), whereas four cases exhibited strong ASS staining (score 2). These results are represented in Supplementary Table S3. Similarly for ASL, 5/57 stained negative (score 0) and correlated with methylation. A further five showed no correlation with methylation and immunohistochemistry. Eight cases were positive for both ASS1 and ASL methylation (Supplementary Table S3).

**ASS1 and ASL CpG island methylation is a predictive biomarker in GBM.** To determine whether methylation of ASS1 and/or ASL affects outcomes of patients, we carried out a statistical analysis as described in Methods. Median overall survival for GBM patients with unmethylated ASS1-CpG island was 496 days versus 309 days for patients with methylated ASS1-CpG island (P = 0.11). Median overall survival for patients with unmethylated ASL-CpG island was
443 days compared with 299 days for patients with methylated ASL CpG island \((P = 0.16)\). Median overall survival for patients whose GBM showed methylation in the CpG islands of both \(ASS1\) and \(ASL\) was significantly shorter than those in whom neither CpG island was methylated or only one of the two CpG islands was methylated. Median overall survival in cases with either CpG island or none methylated \(= 436\) days \textit{versus} 299 days \((P = 0.0468)\) (Figure 7).

**ASS/ASL in non-neoplastic cells.** Gliomas are characterized by a high number of non-neoplastic microglial cells residing within and around the tumour. Previous studies on rat microglia showed that ASS and ASL proteins are upregulated in response to damage.\(^{24}\) We were interested to determine the \(ASS1/ASL\) status of the infiltrating microglia as they could effectively provide an exogenous source of arginine for \(ASS1/ASL\)-negative tumours and negate the effect of ADI-PEG20 treatment. Tissue sections were stained for Iba-1, a macrophage/microglia-specific surface antigen and for ASS. No ASS staining was observed in Iba-1-positive cells, suggesting that microglia within GBM do not/cannot upregulate the \(ASS1\) gene (Figure 6c).

**Discussion**

Despite advances in imaging and surgical techniques and the use of temozolomide, GBM remains a universally and rapidly fatal cancer, affecting patients of all ages. As such, the requirement for novel therapeutic strategies is clear and pressing. Here we show that \(ASS1\) and \(ASL\), encoding the two key enzymatic components of the arginine biosynthetic pathway, are epigenetically regulated in glial brain tumours, and we provide evidence that targeting of this pathway is a novel therapeutic strategy for a subset of patients with this disease. The importance of metabolic changes in brain tumours has been recently illustrated by the detection of gain-of-function mutations in isocitrate dehydrogenase in oligodendrogliomas and the secondary GBM, which develop from a subset of them.\(^{32}\) The present data show that arginine metabolism is disrupted in a proportion of GBM, further emphasizing that abnormalities in fundamental metabolic pathways are a major feature of this disease. A key element of our study is the use of low passage primary cultures of GBM cells. These cultures are established in culture on the day of surgical debulking, closely resemble the primary GBM from which they were established in both expression and methylation of \(ASS1\) and \(ASL\) and in their response to arginine deprivation, analogous to established GBM cell lines and are clearly a more appropriate model for pharmacological studies than cell lines that have been maintained in culture for many years.

We initially identified \(ASS1\) as a transcriptionally down-regulated gene in studies using the demethylating agent 5'AZA to reverse methylation. A number of genes were upregulated that have not been previously described as epigenetically regulated in brain tumours specifically or, more generally, in human cancer. These include, among others, amino butyrate amino transferase (ABAT), EFEMP1 and ZNF365. The significance of silencing of these genes and their role (if any) in the pathogenesis of GBM awaits further analysis.

We show, using two independent techniques (MSP and pyrosequencing), that the \(ASS1\) CpG island is aberrantly methylated in 30% and the \(ASL\) CpG island in 22% of GBM. Only a single study has previously demonstrated...
methylated or only one of the two CpG islands was methylated (\(P = 0.11\)). (b) Median OS for patients with unmethylated ASL CpG island was 443 days compared with 299 days for patients with methylated ASL CpG island (\(P = 0.16\)). (c) Median OS for patients whose GBM showed methylation in the CpG islands of both ASS1 and ASL was significantly shorter than those in whom neither CpG island was methylated or only one of the two CpG islands was methylated (\(P = 0.0468\)). (d) Median OS in cases with either CpG island or none methylated equals 436 days versus 299 days (\(P = 0.18\)).

Trials of the clinical formulation of ADI-PEG20 are in progress in advanced hepatocellular carcinoma, relapsed or refractory small cell lung cancer and malignant pleural mesothelioma (http://clinicaltrials.gov). A number of factors from our work suggest that clinical trial of ADI-PEG20 in GBM is merited. First, a major advantage of the proposed study in GBM is that patients whose cancers exhibit methylation of ASS1 and/or ASL can be further pre-tested for sensitivity to ADI-PE20 in vitro using primary cultures to inform the physician of likely treatment response. Such primary cultures can be established efficiently, rapidly and with a high probability of success from tissue obtained at biopsy or primary debulking. Importantly, sufficient cells to allow predictive pharmacological testing are available within a credible time scale after surgery to inform the use of ADI-PEG20. Second, the extremely unfavourable prognosis for GBM patients correlates with intrinsic resistance to apoptosis of GBM cells.\(^3^\)\(^3\) Clinical trials of CQ in combination with standard therapy showed some improvement in the survival of GBM patients correlates with intrinsic resistance to apoptosis of GBM cells.\(^3^\)\(^3\)\(^3\)\(^3\) Trials of the clinical formulation of ADI-PEG20 are in progress in advanced hepatocellular carcinoma, relapsed or refractory small cell lung cancer and malignant pleural mesothelioma (http://clinicaltrials.gov). A number of factors from our work suggest that clinical trial of ADI-PEG20 in GBM is merited. First, a major advantage of the proposed study in GBM is that patients whose cancers exhibit methylation of ASS1 and/or ASL can be further pre-tested for sensitivity to ADI-PE20 in vitro using primary cultures to inform the physician of likely treatment response. Such primary cultures can be established efficiently, rapidly and with a high probability of success from tissue obtained at biopsy or primary debulking. Importantly, sufficient cells to allow predictive pharmacological testing are available within a credible time scale after surgery to inform the use of ADI-PEG20. Second, the extremely unfavourable prognosis for GBM patients correlates with intrinsic resistance to apoptosis of GBM cells.\(^3^\)\(^3\) Clinical trials of CQ in combination with standard therapy showed some improvement in the survival of GBM patients correlates with intrinsic resistance to apoptosis of GBM cells.\(^3^\)\(^3\)\(^3\)\(^3\) Interestingly, the CQ derivatives quinacrine and mefloquine show superior blood/brain penetration in comparison to CQ and are more potent \textit{in vitro} than CQ in killing GBM cells,\(^3^\)\(^3\)\(^3\)\(^3\) and we propose that combinations of ADI-PEG20 with CQ or CQ derivatives merit consideration for clinical trial in appropriate GBM patients. Third, recurrence of GBM after therapy has been attributed to the presence of chemo-/radio-resistant CD133\(^+\) CSCCs.\(^6\) We have shown in this work that in cells with methylated ASL, CD133\(^+\) GBM cells are growth inhibited by ADI-PEG20 with the same efficiency as CD133\(^+\) , implying that the presence of chemo-/radio-resistant CD133\(^+\) cells will not be a barrier to effective therapy with ADI-PEG20 \textit{in vivo}. Fourth, a major factor limiting

---

**Figure 7** Methylation of ASS1 and ASL CpG island is a predictive biomarker in GBM. To determine whether methylation of ASS1 and/or ASL affects outcomes of patients, Kaplan–Meier curves were used to estimate the probabilities of survival and the log-rank test to assess the statistical significance of differences in event rates using Prism 5. (a) Median overall survival (OS) for GBM patients with unmethylated ASS1 CpG island was 496 days versus 399 days for patients with methylated ASS1 CpG island (\(P = 0.11\)). (b) Median OS for patients with unmethylated ASL CpG island was 443 days compared with 299 days for patients with methylated ASL CpG island (\(P = 0.16\)). (c) Median OS for patients whose GBM showed methylation in the CpG islands of both ASS1 and ASL was significantly shorter than those in whom neither CpG island was methylated or only one of the two CpG islands was methylated (\(P = 0.0468\)). (d) Median OS in cases with either CpG island or none methylated equals 436 days versus 299 days (\(P = 0.18\)).
effective management of GBM is the presence of the blood/brain barrier, which may act to prevent efficient delivery of chemotherapy into the brain. Clearly, as ADI-PEG20 exerts its therapeutic effect by depletion of peripheral blood arginine, passage across the blood/brain barrier is not required for therapeutic efficacy of this agent. Based on these observations, we believe that clinical trial of arginine-deprivation therapy with CQ or CQ derivative compounds is warranted in GBM. CpG island methylation of either ASS1 or ASL, but especially of ASS1 and ASL simultaneously, was associated with particularly poor outcomes in patients treated with the current gold-standard therapy of radiotherapy and temozolomide. We have shown herein that GBM with CpG island methylation of both ASS1 and ASL are hypersensitive to ADI-PEG20, implying that arginine depletion may be an appropriate therapy for patients with particularly poor prognosis disease.

In conclusion, the data we present here identify a new metabolic defect in GBM cells and suggest a novel therapeutic strategy, which circumvents many of the traditional barriers to effective management of this universally fatal malignancy.

Methods

Cell lines, primary cultures and clinical cases. Primary GBM cultures were established from fresh tumours and maintained in DMEM/F12 (1:1) supplemented with 10% foetal bovine serum. In brief, fresh tumour material was washed in RPMI/F12 (1:1) and minced into a cell strainer to obtain a single-cell suspension. Contaminating red blood cells were disrupted using sterile dH20 before cells were transferred to fresh growth medium. Primary cultures were expanded and early passage numbers were frozen in liquid N2 for analysis at a later time point. Globlastoma cell line cells were obtained from the German tissue bank (DSMZ) unless otherwise specified and maintained in RPMI (DBTRG), DMEM (GAMS, SNB19, U87, U116, CCF, LN229), MEM (8MG, T87G), DMEM/F12 (1:1) (MOS95U, M059K) or MEM/RPMI 1:1 (42MG) supplemented with 10% foetal bovine serum (All purchased from Invitrogen, Paisley, UK) and 2.5 mmol/L L-glutamine (Sigma-Aldrich, Dorset, UK).

Sixty GBM cases selected from the Brain Tumour Registry at Imperial College were selected for detailed analysis of enzymes in the arginine biosynthetic pathway. Detailed clinical history, pre-and post-operative imaging and follow-up were available in 60 cases. In all, 24 patients were female and 36 male with mean age 58 years and 7 months (range — 31 years and 1 month—85 years 11 months; median 59 years 7 months). In each case, original H&E-stained sections were re-examined later time point. Glioblastoma cell lines were obtained from the German tissue bank (DSMZ) unless otherwise specified and maintained in RPMI (DBTRG), DMEM (GAMS, SNB19, U87, U116, CCF, LN229), MEM (8MG, T87G), DMEM/F12 (1:1) (MOS95U, M059K) or MEM/RPMI 1:1 (42MG) supplemented with 10% foetal bovine serum (All purchased from Invitrogen, Paisley, UK) and 2.5 mmol/L L-glutamine (Sigma-Aldrich, Dorset, UK).

Methylation analysis. Methylation of the ASS1 and ASL CpG islands was assessed by MSP and quantitative pyrosequencing. All maps of the ASS1 and ASL CpG islands are presented in Supplementary Figure S1. Primers for MSP were designed using MethPrimer software. Primer locations are shown in Supplementary Figure S1 and sequences are listed in Supplementary Table S1. Primers were designed to cover the entire region of the CpG island but only sets 1, 4, 5 and 7 were used for analysis of methylation (Supplementary Figure S1).

Bisulphite modification and MSP. Bisulphite conversion of genomic DNA was carried out using the Zymo EZ DNA methylation kit (Genetix Ltd, Hampshire, UK). This process converts unmethylated cytosine residues to uracil, whereas methylated cytosine residues remain unchanged. MSP was then carried out to determine the methylation status of ASS1 and ASL. In all, 5 µl of bisulphite-modified DNA was used as templates for PCR reactions with primers specific for methylated or unmethylated sequences. CpGenome Universal Methylated DNA and CpGenome Universal Unmethylated DNA were used as positive and negative controls, respectively. PCR conditions were as follows: 8 cycles of 95°C for 1 min, 51.7°C for 30 s and 72°C for 30 s, then a final extension at 72°C for 5 min. PCR products were electrophoresed through 2% agarose gels, stained with ethidium bromide and visualized using a transilluminator.

Analysis of CpG methylation by pyrosequencing. Bisulphite-modified genomic DNA (see above) was used as the template in pyrosequencing. Modified DNA was then subjected to bisulphite sequencing. Bisulphite Sample Prep kit and primers designed to amplify a 145 bp fragment across the CpG island of ASS1 and ASL genes were optimized for software dedicated to methylation analysis. After pyrosequencing, the analysis was performed using Pyr marks Software (Biotage, Uppsala, Sweden). ASS1 forward 5'-TGTGTTTATAATTTGGG ATGG-3' and reverse 5’-GGGTGTAGAGGAGGAG-3’ primers, ASL forward 5’- AGGATTGCGAGGATGAGATGAA-3’ and reverse 5’- CCACTAACCAAACTTTCT AAC-3’ primers. Annealing temperatures were 54°C for ASS1 and 58°C for ASL.

Expression of ASS/ASL was assessed semi-quantitatively where negative tumours are defined as negative with expression ranging between 0-5% (score 0) and diffuse (score 2) those showing expression in 75% or more tumour cells. Anything in between negative and diffuse was defined focal and scored 1.

Analysis of gene expression in vitro. For qPCR, total RNA was prepared from log phase cell lines and primary GBM cultures using the EZNA isolation kit total RNA 1 according to the manufacturer’s instructions (VWR, Leicestershire, UK). cDNA was synthesized from 1 µg of total RNA using anchored oligo(dT) primers and MMLV reverse transcriptase (Invitrogen).
Sensitivity of GBM cells to ADI-PEG20. Cell proliferation was determined at various time points using the sulforhodamine B (SRB) assay (Sigma-Aldrich). ADI-PEG20 was obtained from Polaris Pharmaceuticals Inc. (San Diego, CA, USA). Arginine-free medium was purchased from MP Biomedicals (Cambridge, UK). Cells were seeded in triplicate in 96-well plates at a density of 4 × 10^3 or 4 × 10^3 cells per well for cell lines or primary lines, respectively. Twenty-four hours after seeding, the cells were washed 3 times in PBS and cultured in medium containing varying concentrations of ADI-PEG20 (0–2 μg/ml) or in arginine-free medium supplemented with 1 mM citrulline and 2% dialysed FCS for various time points. Cells were fixed with 10% trichloroacetic acid for at least 1 h at 4°C, washed with distilled water and allowed to dry before being stained with 0.4% SRB. The unbound SRB was washed with 0.1% acetic acid and the plates allowed to air dry. Bound SRB was dissolved in 10 mM tris pH 10.5 and absorbances read at 495 nm.

Caspace inhibition assay. GBM cell lines were seeded at a density of 1.5 × 10^4 cells per well in 6-well tissue-culture-treated plates. Once cells had attached, they were then treated with or without 50 μM Z-VAD-fmk (Bachem, Switzerland) for 24 h in order to inhibit caspase activity. Wells were then treated in the following manner: control (untreated) – / – Z-VAD; citrulline 1 mM – / – Z-VAD; ADI-PEG20 (0.1 μg/ml) – / – Z-VAD. Cells were then left for 48 h under standard culture conditions and harvested for assessment of caspase and non-caspase-mediated cell death. Floating and attached cells (removed by trypsinisation) were then processed for flow cytometric analysis using the Annexin V-FITC Apoptosis Detection kit (Calbiochem, Nottingham, UK). Flow cytometric analysis was carried out using a Coulter EPICS flow cytometer (Beckton Coulter (UK) Ltd, High Wycombe, UK) with FL1 for FITC-annexin staining and FL3 for propidium iodide staining. Samples were analysed in duplicate and the experiments were set up on three separate occasions.

Inhibition of autophagy. Cells were treated with 10 μM CO, 1 μg/ml ADI-PEG20 or both for 24, 48 and 72 h. Cells were harvested, washed in PBS and resuspended in 500 ml PBS and fixed by the addition of 2 ml of cold 90% methanol (Sigma-Aldrich) for 24 h in order to inhibit caspase activity. Wells were then treated in the following manner: control (untreated) – / – Z-VAD; citrulline 1 mM – / – Z-VAD; ADI-PEG20 (0.1 μg/ml) – / – Z-VAD. Cells were then left for 48 h under standard culture conditions and harvested for assessment of caspase and non-caspase-mediated cell death. Floating and attached cells (removed by trypsinisation) were then processed for flow cytometric analysis using the Annexin V-FITC Apoptosis Detection kit (Calbiochem, Nottingham, UK). Flow cytometric analysis was carried out using a Coulter EPICS flow cytometer (Beckton Coulter (UK) Ltd, High Wycombe, UK) with FL1 for FITC-annexin staining and FL3 for propidium iodide staining. Samples were analysed in duplicate and the experiments were set up on three separate occasions.

ASS1 knockdown. Short hairpin RNA (shRNA) sequences targeting ASS1 were cloned into the pSilencer 4.1-CMVpuro vector (Ambion, Life Technologies Ltd). Sequences were designed by Ambion and supplied by Invitrogen (Supplementary Table S1). Control vector expressing an shRNA sequence that does not target any known human gene was used as a negative control in experiments. T98G, U118 and 42MG cells were transfected with shRNA-expressing vectors using Lipofectamine 1000 (Invitrogen). Stably pooled populations of transfecants were obtained following selection with 1 μg/ml puromycin for 3–4 weeks.

Generation of stable GFP-LC3 cells. LN229 cells were transfected with GFP-LC3 (CBA-401) expression vector or empty vector (Cambridge Bioscience, Cambridge, UK). Stable pools of transfecants were obtained following selection with 800 μg/ml of G418 for 3–4 weeks. These were expanded and stored in LN2 until required.

Flow cytometry for CD133 expression. For analysis of CD133 expression and cell sorting by flow cytometry, live cells were trypsinised, washed with cold PBS/1%FCS (wash buffer) and re-suspended at a density of 1 × 10^6 cells/ml in wash buffer. In all, 1 × 10^6 cells were incubated with 100 μl anti-CD133 antibody or mouse IgG1 isotype control (Miltenyi Biotech Ltd (Surrey, UK), diluted 1:100 in wash buffer) for 1 h at 4°C. After the incubation period, cells were washed twice in wash buffer incubated with 100 μl goat-anti-mouse FITC (Sigma-Aldrich) diluted 1:100 in wash buffer. Finally, cells were washed twice in wash buffer and re-suspended in 500 μl PBS/FCS before being analysed by flow cytometry and sorted for CD133-positive and -negative cells.

Statistics. Kaplan–Meier curves were used to estimate the probabilities of survival and time to progression and the log-rank test to assess the statistical significance of differences in event rates using Prism 5 (GraphPad software, Inc., La Jolla, CA, USA).

Written informed consent was received from the participants before inclusion in the study.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements

This work was supported by the Brain Tumour Research Campaign (BTRC) charity.
survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-
NCIC trial. Lancet Oncol 2009; 10: 459–466.
27. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W et al. MGMT
promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev
Neuro 2010; 6: 39–51.
28. Falourmoux P, Bruhat A, Joussel C. Amino acid regulation of gene expression. Biochem J
2000; 351(Pt 1): 1–12.
29. Chaveroux C, Lambert-Langlais S, Cherassie Y, Averous J, Parry L, Carraro V et al.
Molecular mechanisms involved in the adaptation to amino acid limitation in mammals.
Biochimie 2010; 92: 736–745.
30. Briceno E, Reyes S, Sotelo J. Therapy of glioblastoma multiforme improved by the
antimutagenic chloroquine. Neurosurg Focus 2003; 14: e3.
31. Briceno E, Calderon A, Sotelo J. Institutional experience with chloroquine as an adjuvant to
the therapy for glioblastoma multiforme. Surg Neurol 2007; 67: 388–391.
32. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. An
integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:
1807–1812.
33. Geng Y, Kohli L, Klocke BJ, Roth KA. Chloroquine-induced autophagic vacuole
accumulation and cell death in glioma cells is p53 independent. Neuro Oncol 2010; 12:
473–481.

Supplementary Information accompanies the paper on Cell Death and Disease website (http://www.nature.com/cddis)